Scholars Central

Conference abstractPublished 21 Nov 2018

Three-day trial of n-carbamylglutamate improves nitrogen metabolism and decreases ammonia in inherited hyperammonemias and healthy adults

Authors: Leslie Atley, GT Berry, SE McCandless, M Yudkoff, M Tuchman N Ah Mew

Childrens Research Institute, Childrens National Health System, USA; Boston Children’s Hospital, USA; Rainbow Babies and Childrens Hospital, USA; Childrens Hospital of Philadelphia, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Inherited hyperammonemia (HA) from dysfunction of the urea cycle can lead to lethargy, encephalopathy, coma and even death. Current therapy includes ammonia scavenger medications and dietary protein restriction, but these treatments are suboptimal and affected patients still present with recurrent hyperammonemic crises. New therapies are therefore sorely needed. N-acetylglutamate (NAG) is the essential allosteric activator of carbamyl phosphate synthetase I (CPS1), which catalyzes the first step of the urea cycle in the liver. NAG is produced by NAG synthase (NAGS). Absence of or insufficient NAG results in blocked or decreased flux through the urea cycle, with ensuing hyperammonemia. We therefore studied the efficacy of N-carbamylglutamate (NCG), a synthetic analog of NAG, in the treatment of patients with various forms of inherited HA. In order to better understand the effect of NCG in affected patients, we also studied healthy adult volunteers. Methods: We enrolled 34 subjects with inherited hyperammonemias (NAGS deficiency, CPS1 deficiency, ornithine transcarbamylase deficiency, methylmalonic acidemia, and propionic acidemia) and 10 healthy adult subjects. Identical studies were performed immediately before and at the end of a 3-day trial of oral NCG (Carbaglu, Orphan Europe). Following an oral bolus of [13C] sodium acetate, blood samples were collected at pre-determined intervals to measure the levels of [13C] urea, ammonia, urea, and amino acids. Results: NCG reduced blood ammonia levels, reduced glutamine, and increased urea levels in several inherited hyperammonemias. Surprisingly, these same changes, albeit to a smaller degree, were also observed in healthy adult volunteers. Conclusion: NCG improves or restores ureagenesis and decreases or normalizes ammonia in patients with several forms of inherited hyperammonemia. A similar, but smaller magnitude response in healthy adult volunteers, suggests that NCG may even be effective in patients with acquired forms of hyperammonemia, such as liver failure.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Leslie Atley”
  • BylineArticles whose byline prints “GT Berry”
  • BylineArticles whose byline prints “SE McCandless”
  • BylineArticles whose byline prints “M Yudkoff”
  • BylineArticles whose byline prints “M Tuchman N Ah Mew”